Evommune (NYSE:EVMN) Rating Lowered to Sell at Wall Street Zen

Evommune (NYSE:EVMN) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other brokerages also recently weighed in on EVMN. Cantor Fitzgerald started coverage on Evommune in a report on Monday. They set an “overweight” rating for the company. Zacks Research upgraded Evommune to a “hold” rating in a report on Tuesday. Morgan Stanley initiated coverage on shares of Evommune in a research report on Monday. They set an “overweight” rating and a $36.00 price objective for the company. Evercore ISI assumed coverage on shares of Evommune in a report on Monday. They issued an “outperform” rating and a $40.00 price target for the company. Finally, Leerink Partnrs raised shares of Evommune to a “strong-buy” rating in a research note on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $39.33.

Evommune Trading Up 0.2%

EVMN opened at $21.98 on Friday. Evommune has a twelve month low of $16.70 and a twelve month high of $24.03.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.